An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration

An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration

Abstract An 83‐year‐old woman with RET fusion‐positive advanced lung adenocarcinoma was administered selpercatinib 320 mg/day. Despite the shrinking of the tumour, fever, fatigue, and anorexia developed on day 17. Selpercatinib administration was interrupted. On day 21, elevated blood aspartate amin...

Full description

Bibliographic Details
Main Authors: Kazuhisa Nakashima, Yuki Mitarai, Seiko Tanaka, Mika Nakao, Takae Okuno, Tamio Okimoto, Ryo Tanabe, Takashi Yanagawa, Yukari Tsubata, Takeshi Isobe
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Respirology Case Reports
Subjects:
hepatic disorder
lung cancer
old patient
RET fusion
Selpercatinib
Online Access:https://doi.org/10.1002/rcr2.1136

Internet

https://doi.org/10.1002/rcr2.1136

Similar Items